Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

Author： Portaccio Emilio   >  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.23, Iss.6, 2009-05, pp. : 453-462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of interferon-β as a therapy for multiple sclerosis

By Markowitz Clyde  

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 2, 2004-11 ,pp. : 363-374

Informa Healthcare

Access to resources Recommend Favorite

Haematological Effects of Interferon-β-1a (Rebif ® ) Therapy in Multiple Sclerosis

By Rieckmann Peter  

Drug Safety, Vol. 27, Iss. 10, 2004-01 ,pp. : 745-756

Adis International

Access to resources Recommend Favorite

Interferon-β1b for the treatment of multiple sclerosis

By Lam Sum   Wang Shan   Gottesman Malcolm  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 8, 2008-08 ,pp. : 1111-1117

Informa Healthcare

Access to resources Recommend Favorite

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

By Kieseier Bernd C.  

CNS Drugs, Vol. 25, Iss. 6, 2011-06 ,pp. : 491-502

Adis International

Access to resources Recommend Favorite

Interferon-β1b in the treatment of multiple sclerosis

By Río Jordi   Montalban Xavier  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2877-2886

Informa Healthcare

Access to resources Recommend Favorite